In This Article:
NEW YORK, NY / ACCESSWIRE / July 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Ubiquiti Inc. (NYSE:UI)
CONTACT JAKUBOWITZ ABOUT UI:
https://claimyourloss.com/securities/ubiquiti-inc-loss-submission-form/?id=17600&from=1
Class Period : January 11, 2021 - March 20, 2021
Lead Plaintiff Deadline: July 19, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had downplayed the data breach in January 2021; (2) attackers had obtained administrative access to Ubiquiti's servers and obtained access to, among other things, all databases, all user database credentials, and secrets required to forge single sign-on (SSO) cookies; (3) as a result, intruders already had credentials needed to remotely access Ubiquiti's customers' systems; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Provention Bio, Inc. (NASDAQ:PRVB)
CONTACT JAKUBOWITZ ABOUT PRVB:
https://claimyourloss.com/securities/provention-bio-inc-loss-submission-form/?id=17600&from=1
Class Period : November 2, 2020 - April 8, 2021
Lead Plaintiff Deadline: July 20, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Home Point Capital Inc. (NASDAQ:HMPT)
CONTACT JAKUBOWITZ ABOUT HMPT:
https://claimyourloss.com/securities/home-point-capital-inc-loss-submission-form/?id=17600&from=1